- Home
- PSEC vs RIGL Comparison
PSEC vs RIGL Comparison
Compare PSEC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSEC | RIGL |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 771.4M | 911.8M |
| IPO Year | 2012 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PSEC | RIGL |
|---|---|---|
| Price | $1.41 | $39.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $63.00 |
| AVG Volume (30 Days) | ★ 6.7M | 180.6K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 30.32% | N/A |
| EPS Growth | 104.44 | ★ 1867.68 |
| EPS | N/A | ★ 1.97 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | $3.89 |
| Revenue Next Year | N/A | $21.95 |
| P/E Ratio | ★ N/A | $38.86 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $1.40 | $24.84 |
| 52 Week High | $3.13 | $52.61 |
Technical Indicators
Market Signals| Indicator | PSEC | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 24.88 | 30.50 |
| Support Level | N/A | $33.93 |
| Resistance Level | $2.33 | $43.74 |
| Average True Range (ATR) | 0.09 | 2.29 |
| MACD | 0.00 | -0.80 |
| Stochastic Oscillator | 20.27 | 15.96 |
Price Performance
Historical ComparisonAbout PSEC Prospect Capital Corporation
Prospect Capital Corp is a financial services company that mainly lends to and invests in middle market privately-held companies. It is a closed-end investment company. Its investment objective is to generate both current income and long-term capital appreciation. It has single operating and reporting segment.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.